Endocrinopathy-induced euvolemic hyponatremia

Euvolemic hyponatremia is a clinical condition marked by low serum sodium levels without volume depletion. The condition is often attributed to the syndrome of inappropriate antidiuretic hormone secretion (SIADH), hypothyroidism, or adrenal insufficiency. Standard diagnostic protocols require the exclusion of endocrine causes before confirming SIADH. Despite this, the frequency of endocrinopathy-induced euvolemic hyponatremia remains unclear in clinical settings. Prior research has established that SIADH is a common diagnosis in such cases. However, the extent to which thyroid or adrenal dysfunction contributes to hyponatremia in real-world patient populations is not well documented. No prior work had resolved whether routine endocrine testing in these patients is beneficial or necessary. That uncertainty drove this study to evaluate the yield of endocrine testing in patients diagnosed with euvolemic hyponatremia. This gap motivated the investigation into how often endocrinopathies are identified in such cases. The study aimed to clarify whether endocrine testing is underutilized and whether it leads to actionable diagnoses. This background sets the stage for assessing the real-world relevance of endocrine evaluations in euvolemic hyponatremia cases.

This study aimed to evaluate the frequency of endocrinopathy-induced euvolemic hyponatremia in a tertiary hospital setting. The researchers sought to determine how often thyroid and adrenal function tests are performed in patients with this condition. They also wanted to assess whether these tests lead to a diagnosis of hypothyroidism or adrenal insufficiency. The motivation for this work stems from the diagnostic criteria for SIADH, which require ruling out endocrine causes. However, prior data on the yield of these tests in clinical practice is limited. The study focused on a real-world cohort of patients diagnosed with euvolemic hyponatremia. The primary goal was to quantify how often endocrine testing identifies an underlying endocrinopathy. The researchers also aimed to evaluate whether these findings influence clinical management. This purpose aligns with the broader goal of improving diagnostic accuracy in hyponatremia cases.

The study used a retrospective design to analyze medical records from a single tertiary hospital. The researchers included all patients diagnosed with euvolemic hyponatremia between January 2007 and January 2013. Data collected included demographic information, clinical history, and laboratory results. Thyroid function tests were performed in 69% of cases, while adrenal function tests were conducted in 29% of cases. The researchers reviewed whether endocrinopathy was diagnosed based on these tests. Patients with confirmed hypothyroidism or adrenal insufficiency were identified. The study also examined whether these patients exhibited symptoms beyond hyponatremia. The researchers evaluated whether hormone replacement therapy resolved the hyponatremia. This approach allowed them to assess the clinical yield of endocrine testing in this population.

Out of 564 patients with euvolemic hyponatremia, nine (1.6%) were diagnosed with endocrinopathy-induced hyponatremia. Three patients had hypothyroidism, three had adrenal insufficiency, and three had central hypothyroidism and central hypoadrenalism. Thyroid function tests were performed in 69% of cases, but only three cases were diagnosed with hypothyroidism. Adrenal function tests were performed in 29% of cases, with three cases of adrenal insufficiency identified. All nine patients had symptoms and medical histories consistent with endocrine deficiencies. Hyponatremia resolved within 1–3 days after hormone replacement therapy. The overall yield of endocrine testing was low, with diagnoses occurring only in patients with additional clinical findings. The researchers observed that a limited number of patients underwent full endocrine evaluation, suggesting potential underdiagnosis.

The study found that endocrinopathy-induced euvolemic hyponatremia is rare in clinical practice. Only 1.6% of patients with euvolemic hyponatremia had an underlying endocrinopathy. Thyroid and adrenal testing were performed in a minority of cases, with low diagnostic yield. The researchers noted that diagnoses occurred only in patients with additional clinical signs of endocrine deficiency. Hyponatremia resolved rapidly with hormone replacement therapy in these cases. The findings suggest that endocrine testing is underutilized in this patient population. However, the study does not support changing current guidelines for universal endocrine evaluation. The authors propose that further research is needed to clarify the diagnostic value of these tests. These conclusions align with the study's aim to assess the real-world yield of endocrine testing in euvolemic hyponatremia.